{
  "docId": "019de074-dee8-7497-a5f7-ae2745d7f9f6",
  "docSlug": "87d7e2eb7c56e30923dbf29903df5034",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 40 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 37,
  "pageCount": 40,
  "prevPage": 36,
  "nextPage": 38,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 5,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-dee8-7497-a5f7-ae2745d7f9f6/37",
  "deckHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6",
  "deckJsonHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6.json",
  "deckAnchorHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6#slide-37",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.03,
        "y": 0.288
      },
      "kind": "list",
      "text": "IND enabling activities: NHP dose range finding study completed, PD-1 shedding confirmed in vivo, Manufacturing campaign completed, Pre-IND meeting completed, Toxicology studies underway",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6cac4d9e-0e7b-4277-a5ba-cb8edfe453fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.52,
        "y": 0.288
      },
      "kind": "list",
      "text": "Phase 1 study planning: Multiple ascending dose, dose-escalation study, 5 doses planned: 0.1, 0.3, 1.0, 3.0, and 10 mg/kg, Post PD-1 or PD-L1 patient population, PD-1 shedding on peripheral T cells was confirmed in NHP",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7755fefc-5771-4fee-ae48-65caa1946373",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.56,
        "x": 0.22,
        "y": 0.775
      },
      "kind": "paragraph",
      "text": "IND submission targeted for Q3 2023. Potential for proprietary combination regimens with CTX-009 and CTX-471",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0292ef0d-1178-495a-97c6-9b48760b9d43",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.47,
        "x": 0.04,
        "y": 0.13
      },
      "kind": "title",
      "text": "CTX-8371: Development Status",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32b3b22d-6fc0-4705-8df7-5356920561a8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}